Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Analysis of mechanisms of Shenhuang Granule in treating severe COVID-19 based on network pharmacology and molecular docking

Xiang-ru Xu, Wen Zhang, Xin-xin Wu, Hong-qiang Yang, Yu-ting Sun, Yu-ting Pu, Bei Wang, Wei Peng, Li-hua Sun, Quan Guo, Shuang Zhou, Bang-jiang Fang

Department of Emergency, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China
Acupuncture and Massage College, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
Institute of Critical Care, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China

Article history:
Received 13 December 2021
Accepted 15 June 2022
Available online 28 July 2022

Keywords:
COVID-19
SARS-CoV-2
Shenhuang granule
Mechanism
Network pharmacology
Molecular docking
Molecular dynamics simulation

Abstract

Objective: Severe cases of coronavirus disease 2019 (COVID-19) are expected to have a worse prognosis than mild cases. Shenhuang Granule (SHG) has been shown to be a safe and effective treatment for severe COVID-19 in a previous randomized clinical trial, but the active chemical constituents and underlying mechanisms of action remain unknown. The goal of this study is to explore the chemical basis and mechanisms of SHG in the treatment of severe COVID-19, using network pharmacology.

Methods: Ultra-performance liquid chromatography-quadrupole time-of-flight mass spectrometry was employed to screen chemical constituents of SHG. Putative therapeutic targets were predicted by searching traditional Chinese medicine system pharmacology database and analysis platform, SwissTargetPrediction, and Gene Expression Omnibus (GEO) databases. The target protein–protein interaction network and enrichment analysis were performed to investigate the hub genes and presumptive mechanisms. Molecular docking and molecular dynamics simulations were used to verify the stability and interaction between the key chemical constituents of SHG and COVID-19 protein targets.

Results: Forty-five chemical constituents of SHG were identified along with 131 corresponding therapeutic targets, including hub genes such as HSP90AA1, MMP9, CXCL8, PTGS2, IFNG, DNMT1, TYMS, MDM2, HDAC3, and ABCB1. Functional enrichment analysis indicated that SHG mainly acted on the neuroactive ligand-receptor interaction, calcium signaling pathway and cAMP signaling pathway. Molecular docking showed that the key constituents had a good affinity with the severe acute respiratory syndrome coronavirus 2 protein targets. Molecular dynamics simulations indicated that ginsenoside Rg4 formed a stable protein–ligand complex with helicase.

Conclusion: Multiple components of SHG regulated multiple targets to inhibit virus invasion and cytokine storm through several signaling pathways; this provides a scientific basis for clinical applications and further experiments.

1. Introduction

The pandemic of coronavirus disease 2019 (COVID-19) has caused worldwide concern. As of November 2021, there have been over 248 million confirmed cases and more than 5 million deaths worldwide [1]. An early cohort study of patients with COVID-19 showed that 14% had severe disease, 5% had critical disease, and the mortality of the critically ill cases was 49% [2]. Severe COVID-19 cases are expected to have a worse prognosis than milder cases. A systematic review of global COVID-19 infections showed that 67.7% of patients admitted to intensive care units required invasive mechanical ventilation, 65.9% required vasopressor support, 16.9% required renal replacement therapy, and 6.4%...
required extracorporeal membrane oxygenation [3]. Therapeutic considerations for severe and critical COVID-19 include supportive care, corticosteroids, remdesivir and tocilizumab [4]. Although remarkable advances have been made in reducing mortality and enhancing recovery from symptoms, no drugs have been developed to treat the infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Traditional Chinese medicine (TCM) has gained important experience in managing the COVID-19 epidemic in China. According to the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (8th edition), Qingfei Paidu Decoction, Xuanfei Paidu Formula, Huashi Baidu Formula, Jinhuia Qinggan Granule, Lianhua Qingswen Capsule and Xuebijing Injection, referred to as “three Chinese patent medicines and three decoctions,” are recommended for treating the disease [5]. Among these, Xuebijing Injection and Huashi Baidu Formula are used mainly for severe COVID-19 [6,7], while Qingfei Paidu Decoction can be used for patients at any clinical stage [8]. In the early stage of outbreaks, our group developed the Shenhuan Granule (SHG) to treat severe COVID-19. We also conducted a multicenter, prospective and randomized clinical trial to confirm the efficacy and safety of SHG in patients with severe COVID-19 [9]. The result reflected an increased recovery rate and a decreased mortality in severe and critical cases. Further, SHG was able to reduce the rate of disease progression from the severe category to the critical category.

SHG is composed of Radix Ginseng, Radix Aconiti Lateralis Preparata, Rhei Radix Et Rhizoma, Caulis Sargentodoxae, Herba Taraxaci and Hirudo. As a complex herbal mixture containing multiple chemical constituents that act on numerous targets and pathways, SHG may be effective against COVID-19. However, the active chemical constituents, putative targets and biological mechanisms of SHG remain unknown and need further investigation. Network pharmacology is a new subject based on systems biology, computational biology and systems pharmacology. Network pharmacology explores the pharmacological characteristics and mechanisms of TCM prescriptions in the treatment of diseases from a systematic and comprehensive point of view by constructing a “disease-function-target-constituent-herb” interaction network, analyzing the topological parameters, and calculating the relevance between the specific signal nodes in the network [10]. Then, the key chemical constituents in the network and the core targets of the disease are selected for molecular docking simulation, in order to obtain the potential effective chemical constituents and targets for further experimental verification. Recent network pharmacology studies have preliminarily illustrated the interaction mechanisms between small molecules from Chinese medicines and COVID-19 disease targets. For example, quercetin and baicalein, present in the Huashi Baidu Formula, were found to have a strong affinity for angiotensin-converting enzyme 2 (ACE2) and SARS-CoV-2 3-chymotrypsin-like protease protein [11]. Baicalein, luteolin and quercetin in the Xuebijing Injection may inhibit the excessive inflammatory response associated with COVID-19 by regulating AKT1 expression [12]. Four compounds (baicalein, glycyrrhetic acid, hesperidin and hyperoside) in the Qingfei Paidu Decoction have interactions with different SARS-CoV-2 targets [13]. These results provide a new rationale for Chinese medicine to treat COVID-19.

In this study, we identified the main chemical constituents of SHG by ultra-performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF-MS). Putative therapeutic targets were predicted from several databases. Then, network pharmacology methods, molecular docking, and molecular dynamics simulations were integrated to investigate the mechanisms of SHG on severe COVID-19 and verify the stability and interaction between the key chemical constituents and COVID-19 protein targets.

2. Materials and methods

2.1. Materials and chemicals

Liquid chromatography-mass spectrometry (LC-MS) grade methanol and acetonitrile were provided by Merck KGaA (Shanghai, China). The same grade methanoic acid (Y9330090) was purchased from Thermo Fisher Scientific Co., Ltd (Shanghai, China). The deionized water (20210402C) was provided by Guangzhou Watsons Food & Beverage Co., Ltd (Guangzhou, China).

2.2. Preparation of SHG extraction

This study investigated the Chinese patent medicine SHG, which is composed of Radix Ginseng (Renshen) 50 g, Rhei Radix Et Rhizoma (Dahuang) 40 g, Radix Aconiti Lateralis Preparata (Fuzi) 50 g, Caulis Sargentodoxae (Daxuuteng) 30 g, Herba Taraxaci (Pugongying) 30 g, and Hirudo (Shuizhi) 6 g. SHG was produced by Beijing Tcmages Pharmaceutical Co. Ltd (Beijing, China). Quality assurance test results for each drug were consistent with the required quality standards. The product was approved by the National Medical Product Administration (China; Approval number: Jing 20180032).

2.3. UPLC-Q-TOF-MS identification of major SHG constituents

A 0.5 g sample of SHG was added to 25 mL of 80 % methanol in a 50 mL corked conical flask. The SHG was solubilized with ultrasound (300 W, 40 kHz) for 30 min. Then the SHG solution was centrifuged at 13,000 × g for 5 min to obtain supernatant. Analysis was performed on an Agilent 1290 UPLC system (Agilent, USA) in tandem with an AB Sciex Triple TOP® 4600 mass spectrometer (AB SCIEX, USA). Experimental parameters were set according to Hao et al [14]. UPLC parameters were as follows: a Waters Acquity UPLC HSS T3 column (2.1 mm × 100 mm, 1.8 μm), with a flow rate of 0.3 mL/min, column temperature 30 °C, and detection wavelength from 190 – 400 nm. Mobile phase A was 0.1 % methanoic acid in water, and phase B was 0.1 % methanoic acid in acetonitrile. The gradient elution protocol was as follows: 0–14 min, 5%–20% B; 14–39 min, 20%–60% B; 39–46 min, 60%–95% B; 46.1–48 min, 95%–5% B. Mass spectrometry (MS) conditions were as follows: time-of-flight mass range, 50–1700; ion source gas 1, 2.394 kPa; ion source gas 2, 2.394 kPa; curtain gas, 1.676 kPa; ion spray voltage floating, –4500/5000 V; ion source temperature, 500 °C; declustering potential, 100 V; MS/MS mass range, 50–1250; collision energy, ± 40 eV. MS data were collected using an Analyst TF 1.7.1 (AB SCIEX, Foster City, CA, USA) and processed using Peakview 1.2 (AB SCIEX, USA). The main peaks in the fingerprints were identified and authenticated using the Natural Products HR-MS/MS Spectral Library 1.0 software (Shanghai Standard Technology Co., Ltd., Shanghai, China), which contains over 1000 standard substances. Chemical constituents that were not found in the database were identified using literature reports and the fragmentation patterns in MS.

2.4. Screening of putative targets in SHG

The traditional Chinese medicine system pharmacology database and analysis platform (TCMSP) [15], and the SwissTargetPrediction database (https://www.swisstargetprediction.ch/) [16] were used to identify the putative targets of the main constituents of SHG. The protein target corresponding to each constituent was translated into a gene name using the UniProt database (https://www.uniprot.org/).
2.5. Screening of severe COVID-19 disease targets

The gene expression array datasets of severe COVID-19 were searched using the Gene Expression Omnibus (GEO) database (https://www.ncbi.nlm.nih.gov/geo/) [17]. Microarray data for differentially expressed long noncoding RNAs (lncRNAs) in the peripheral blood mononuclear cells between the severe COVID-19 group and the healthy group were obtained from GEO Series GSE164805 (PMID: 33679778) [18]. The GEO2R online tool was used to detect the genes that are differentially expressed between the two groups, and genes with an adjusted P < 0.05 and |log2(fold change)| > 2, were considered significantly differentially expressed and potential drug targets in severe COVID-19. Finally, the volcano map of significantly differentially expressed genes was visualized using the NetworkAnalyst platform (https://www.networkanalyst.ca/NetworkAnalyst/home.xhtml) [19].

2.6. Construction of SHG herb-constituent-target network

The therapeutic targets of SHG in the treatment of severe COVID-19 were obtained by intersecting the putative targets of the chemical constituents with the disease targets. A Venn diagram was then prepared using the Venn diagram webtool (https://bioinformatics.psb.ugent.be/cgi-bin/liste/Venn/). The SHG herb-constituent-target network was constructed to illustrate the relationship between the herb chemical constituents and the severe COVID-19 disease targets. Cytoscape 3.8.2 software [20] was used to construct the herb-constituent-target network, and the network degree parameter was calculated. Deeper colors and larger node areas represent greater connectivity among targets and chemical constituents.

2.7. Construction of the protein–protein interaction network and identification of hub genes

The protein–protein interaction (PPI) network of the therapeutic targets was obtained using the STRING database (https://string-db.org/) [21]. The therapeutic targets were input into STRING to remove the poorly connected targets and the threshold of an interaction score of > 0.4 was used. The PPI network was visualized using Cytoscape 3.8.2. The CytoNca plugin was used to calculate the degree of each protein node and screen the hub genes. Three important parameters that represented the topological importance of the nodes in the network were selected, including betweenness centrality, closeness centrality and degree centrality. We selected the top ten genes as the hub genes. The relationship between hub genes and chemical constituents of SHG is shown through the Sankey diagram.

2.8. Construction of target-organ network

Considering that COVID-19 is a systemic disease, multiple tissues and organs may suffer different degrees of damage over the course of severe COVID-19. We used the BioGPS database (https://biogps.org) [22] to analyze the tissue-specific expression and the distribution of the 131 therapeutic targets. The screening criteria were as follows: the tissue-specific expression level was > 10 times the median; if not, the top 3 expression levels were extracted. The constituent target-organ network was visualized using Cytoscape 3.8.2. The number of adjacent nodes in the network was calculated, and the size of the nodes in the network was determined according to the number of adjacent nodes.

2.9. Gene Ontology and Kyoto Encyclopedia of genes and Genomes enrichment analysis

The Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) terms were applied to the annotated target proteins at the functional level. The ClusterProfiler package [23] of R 3.6.3 was used to analyze the GO and KEGG enrichment. An adjusted P < 0.05 and a q value < 0.2 were considered as a threshold for restriction. The top 20 GO pathways in the biological process (BP), cellular composition (CC) and molecular function (MF) as well as the top 20 KEGG pathways were retained.

2.10. Physicochemical property and ADMET evaluation of the main chemical constituents in SHG

Based on the MolSoft website (https://molsoft.com/mprop/), the drug-likeness scores of the main chemical constituents in SHG were calculated by querying simplified molecular input line entry system. Based on the ADMETlab 2.0 server (https://admetmesh.scbdd.com/) [24], the physicochemical properties of each compound were predicted, including molecular weight, number of hydrogen bond acceptors, number of hydrogen bond donors, LogP, LogS and number of stereo centers. In addition, the ADMET parameters were predicted, namely absorption, distribution, metabolism, excretion and toxicity.

2.11. Molecular docking

The key chemical constituents with more than the median degree, betweenness centrality and closeness centrality were selected from the herb-constituent-target network, and the SDF files of these constituents were downloaded from the PubChem database (https://pubchem.ncbi.nlm.nih.gov/) and then uploaded to the COVID-19 Docking Server website (https://ncov.schanglab.org.cn/index.php) [25] for molecular docking. The COVID-19 Docking Server website serves as a platform for docking small molecules, peptides, or antibodies to COVID-19 protein targets and provides a prediction of target-ligand interactions. The protein targets include 1 structural protein (nucleocapsid protein [N protein]) and 8 nonstructural proteins (main protease [Mpro], papain-like protease [PLpro], nonstructural protein 3 [Nsp3], RNA-dependent RNA polymerase [RdRp], helicase, Nsp14, Nsp15 and Nsp16) that are considered ideal targets for developing anti-viral drugs. The Nsp3 has two binding sites, referred to as adenosine monophosphate (AMP) and 2-(N-morpholino)-ethanesulfonic acid acid sites. The RdRp has two binding sites referred to as RdRp without RNA and RdRp with RNA. The helicase has two binding sites, called adenosine diphosphate and nucleic acid binding sites. The Nsp14 has two binding sites, called N-terminal exoribonuclease and guanine-N7 methyl transferase sites. The corresponding

2.12. Molecular dynamics simulation

The molecular dynamics simulation was used to verify the stability and dynamic interactions between the proteins and ligands after molecular docking. The molecular dynamics simulation was performed using the GROMACS 2018.8 software (https://www.gro-
The system was solvated using the TIP3P water model in a dodecahedron box, and appropriate numbers of Na+/Cl− ions were added to neutralize charges. The system was energy-minimized using the steepest descent method of 50,000 steps and < 10.0 kJ/mol force and subsequently equilibrated using 100 ps of canonical and isothermal-isobaric simulations at the temperature of 300 K. Finally, the molecular dynamics simulation was carried out using a leap-frog algorithm for 10 ns with a time step of 2 fs. The resulting molecular dynamics trajectories were analyzed for several parameters including root-mean-square deviation and root-mean-square fluctuation. The Gibbs free energy was calculated according to the values of root-mean-square deviation and radius of gyration (Rg). Xmgrace 5.1.22 (https://plasma-gate.weizmann.ac.il/Grace/) and Origin 8.5.1 (OriginLab, USA) were used for visualization.

3. Results

3.1. Information on chemical constituents and putative targets of SHG

A total of 45 main chemical constituents of SHG were detected by UPLC-Q-TOF-MS (Table 1). The base peak chromatograms of SHG under both positive- and negative-ion modes are shown in Fig. 1. Among these chemical constituents, we could not determine the molecular structures of 10 constituents (Table S3). The molecular structures of the known chemical constituents of SHG are shown in Table 1. The results were visualized by using the GraphPad Prism 9.0.0 and OriginLab 9.1.5 software.

### Table 1

| No. | Measured mass (m/z) | Error (%) | Molecular formula | Molecule name | Herb | PubChem CID |
|-----|---------------------|-----------|-------------------|---------------|------|-------------|
| 1   | 331.0871            | 0.0030    | C_{17}H_{20}O_{12} | O-Galloylglucose | Rhei Radix Et Rhizoma | 21120349 |
| 2   | 169.0142            | 0.0070    | C_{7}H_{8}O_{4}   | Gallic acid    | Rhei Radix Et Rhizoma | 370 |
| 3   | 164.0717            | 0.0049    | C_{9}H_{12}N_{2}O_{3} | Phenylpropanoic acid | Hirudo | 6140 |
| 4   | 355.0878            | 0.0014    | C_{17}H_{20}O_{12} | Neochromogenic acid | Herba Taraxaci/Caulis Sargentodoxae | 5208633 |
| 5   | 486.2698            | -0.0051   | C_{32}H_{46}O_{18} | Mesaconase | Radix Aconiti Lateralis Preparata | 76189547 |
| 6   | 299.1136            | 0.0026    | C_{9}H_{14}O_{7}  | Salidroside | Caulis Sargentodoxae | 159278 |
| 7   | 289.0718            | 0.0036    | C_{15}H_{22}O_{15} | Catechin | Herba Taraxaci/Caulis Sargentodoxae | 1203 |
| 8   | 355.0878            | 0.0040    | C_{17}H_{20}O_{12} | Chlorogenic acid | Herba Taraxaci/Caulis Sargentodoxae | 1794427 |
| 9   | 355.0878            | 0.0020    | C_{17}H_{20}O_{12} | Luteolin | Herba Taraxaci/Caulis Sargentodoxae | 9798666 |
| 10  | 454.2799            | -0.0036   | C_{21}H_{24}O_{12} | Fuzilin | Radix Aconiti Lateralis Preparata | 14163819 |
| 11  | 787.2666            | 0.0020    | C_{56}H_{68}O_{37} | Eleutherose E | Caulis Sargentodoxae | 71312557 |
| 12  | 473.0725            | 0.0010    | C_{32}H_{46}O_{24} | Chicosin | Herba Taraxaci | 5281764 |
| 13  | 431.0984            | 0.0040    | C_{21}H_{24}O_{12} | Aloe-emodin-8-0-ß-D-glucopyranoside | Rhei Radix Et Rhizoma | 5317644 |
| 14  | 445.0776            | 0.0030    | C_{21}H_{24}O_{12} | Rhein-8-0-ß-D-glucopyranoside | Rhei Radix Et Rhizoma | 348579006 |
| 15  | 590.2960            | -0.0030   | C_{21}H_{24}O_{12} | Benzoylmesaconine | Radix Aconiti Lateralis Preparata | 24832659 |
| 16  | 431.0984            | 0.0024    | C_{21}H_{24}O_{12} | Emodin-1-0-glucoside | Rhei Radix Et Rhizoma | 5319333 |
| 17  | 604.3116            | -0.0030   | C_{32}H_{46}O_{24} | Benzoylchrysophanol | Radix Aconiti Lateralis Preparata | 20055771 |

*: Chemical constituents without a specific molecular structure. Numbers in the No. column are the same as the peak numbers in Fig. 1.
the specific molecular structure for peaks 41, 43 and 18. Further, components numbered 24 and 36 were not found on the PubChem website and were drawn from the SwissTargetPrediction database. Searches of the TCMSP and SwissTargetPrediction databases returned 829 targets for the 42 chemical constituents, after removing duplicate values.

3.2. Potential target genes of severe COVID-19

The analysis of the gene chip in the GEO database (GSE164805) identified 6160 differentially expressed genes related to severe COVID-19, which were used to build a volcano plot (Fig. 2). These significantly differentially expressed genes are marked with red dots for upregulated genes and blue dots for downregulated genes.

3.3. Herb-constituent-target network construction

The constituent targets of SHG were matched with the disease targets of severe COVID-19, resulting in the selection of 131 therapeutic targets (Fig. 3). The herb-constituent-target network of SHG against severe COVID-19 was constructed to illustrate the relationship between the main chemical constituents and the target proteins. The network contained 182 nodes (6 herbs, 45 main chemical constituents, and 131 target proteins) and 761 edges (Fig. 4). The red nodes represented the herbs. The peripheral rings were chemical constituents of the herbs. In the inner layer, the blue squares represented target proteins. The dark purple and brown hexagons indicate the constituent that existed in multiple herbs. Supplementary Table S1 shows the main chemical constituents of SHG and their corresponding therapeutic targets.

3.4. PPI network construction and hub gene identification

Protein interactions among the therapeutic targets were predicted using the STRING database and visualized using Cytoscape. A total of 108 nodes and 329 edges were involved in the PPI network after removing the unconnected targets (Fig. 5A). CytoNca was used to calculate the degree of each node. The larger the node area and the redder the color, the more important the target protein is anticipated to be. The top ten genes, heat-shock protein 90α family class A member 1 (HSP90AA1), matrix metallopeptidase 9 (MMP9), C-X-C motif chemokine ligand 8 (CXCL8), prostaglandin-endoperoxide synthase (PTGS2), interferon γ (IFNG), recombinant DNA methyltransferase 1 (DNMT1), Homo sapiens thymidylate synthetase (TYMS), murine double minute 2 (MDM2), histone deacetylase 3 (HDAC3) and ATP-binding cassette subfamily B member 1 (ABCB1), as evaluated by the degree of interaction in the PPI network, were identified as hub genes (Fig. 5C). The Sankey diagram shows the relationship between hub genes, chemical constituents and herbs (Fig. 5B).

3.5. Target-organ location network construction

The tissue-specific expression and distribution of the 131 therapeutic targets were analyzed in BioGPS. PDE11A and TLR9 did not have suitable expression profiles in BioGPS. The expression of the remaining 129 targets in a specific tissue or organ system is shown in Supplementary Table S2. Expression of the target proteins was evaluated in specific tissue or organ systems, including the brain, lymphoid tissues, heart, gastrointestinal tract, endocrine tissues, liver, muscle tissues, whole blood, lung, bronchial epithelial cells,
adipocyte, male tissues, placenta, nerve tissues, female tissues, eye, bone marrow and kidney. In addition, the targets were highly related to immunocytes, including 721-B-lymphoblasts, CD34+ cells, CD33+ myeloid cells, CD71+ early erythroid cells, CD105+ endothelial cells, BDCA4+ dendritic cells, CD4+ T cells, CD56+ NK cells, CD8+ T cells, CD19+ B cells and MOLT-4 cells. Then, the target-organ location network, which contained 162 nodes and 320 edges, was constructed to exhibit the relationship between targets and tissues (Fig. 6). The blue squares represent target proteins. The peripheral rings indicate tissue or organ locations. Size of the tissue and organ nodes is relative to the degree of network connectivity.

3.6. GO and KEGG enrichment analysis

A total of 1103 BP entries, 44 CC entries and 108 MF entries were obtained through the GO enrichment analysis. The KEGG functional enrichment analysis contained 63 items. We selected the top 20 functional enriched terms in the BP, CC and MF categories to draw a bubble diagram (Fig. 7A–C; Supplementary Table S3). Based on the clustering analysis, BPs were mainly involved in second-messenger-mediated signaling, response to oxygen levels, response to antibiotic, regulation of synaptic transmission, metabolic process, neutrophil activation, and regulation of membrane potential. The CC domain was mainly enriched in the neuronal cell body, synaptic membrane, external side of plasma membrane, and presynapse. The MF domain was mainly involved in phosphoric ester hydrolase activity, endopeptidase activity, amide and peptide binding, and active transmembrane transporter activity. The top 20 KEGG pathways are shown in Fig. 7D and Supplementary Table S4, including neuroactive ligand-receptor interaction, calcium signaling pathway, cAMP signaling pathway, prostate cancer, purine metabolism, alcoholism, interleukin-17 (IL-17) signaling pathway, thyroid hormone signaling pathway, forhead box O (FoxO) signaling pathway, dopaminergic synapse, apoptosis, estrogen signaling pathway, fluid shear stress and atherosclerosis, gastric cancer, morphine addiction, small cell lung cancer, toll-like receptor (TLR) signaling pathway, C-type lectin receptor (CLR) signaling pathway, T cell receptor (TCR) signaling pathway, and tumor necrosis factor (TNF) signaling pathway. These pathways involve the immune system, signal transduction, cancers, endocrine and nervous system, cell growth and death, cardiovascular disease, metabolism, and substance dependence. The size of the nodes was decided by the number of associated genes, and the colors from red to blue reflected the P-values from high to low.

3.7. Physicochemical property and ADMET evaluation of the main chemical constituents

Physicochemical property statistics of the main chemical constituents in SHG are shown in Supplementary Table S5. Among the 42 chemical constituents in SHG, 33 chemical constituents were predicted to possess a positive drug-likeness score. ADMET parameters, including absorption (Caco-2 permeability, human
intestinal absorption, and Madin-Darby canine kidney), distribution (plasma protein binding, volume distribution, blood brain barrier, and fraction unbound in plasma), excretion (clearance, and half-life of a drug), and toxicity (human hepatotoxicity, Ames toxicity, rat oral acute toxicity, skin sensitization, eye irritation, and respiratory toxicity) are shown in Supplementary Table S6.

3.8. Molecular docking

To further assess the interaction between the chemical constituents and the targets, 10 key chemical constituents according to topological analysis and 15 protein targets from the COVID-19 Docking Server were selected for docking. The topology parameters of the 10 key chemical constituents in the herb-constituent-target network are shown in Table 2. The docking scores between these key chemical constituents of SHG and SARS-CoV-2 protein targets are shown in Table 3. Chemical constituents with lower binding energies are usually considered to exhibit a higher binding affinity with the protein targets [28]. The affinity scores of the best six modes, chikusetsusaponin Iva-RdRp with RNA, ginsenoside Rf-RdRp with RNA, ginsenoside Rg4-helicase (nucleic acid binding site), ginsenoside Rh4-PLpro, ginsenoside Rg4-Nsp16 (GTA site), and ginsenoside Rg4-Nsp16 (SAM site), were all greater than –9.8 kcal/mol, which indicates that these chemical constituents had a good affinity with the SARS-CoV-2 protein targets (Fig. 8).

According to statistical analysis in the PDB database, hydrophobic contacts and hydrogen bonds were the most frequent type of interactions observed in protein-ligand atomic interactions [29]. As shown in Fig. 8, compound ginsenoside Rf bound to RdRp with RNA formed 8 hydrogen bonds and 11 hydrophobic contacts. Chikusetsusaponin Iva bound to RdRp with RNA formed 6 hydrogen bonds and 7 hydrophobic contacts. Ginsenoside Rh4 bound to PLpro formed 6 hydrogen bonds and 10 hydrophobic contacts. Ginsenoside Rg4 bound to three sites in two molecules: when bound to helicase, it formed 6 hydrogen bonds and 11 hydrophobic contacts; when bound to Nsp16 (GTA site), it formed 8 hydrogen bonds and 10 hydrophobic contacts; when bound to Nsp16 (SAM site), it formed 6 hydrogen bonds and 12 hydrophobic contacts.

3.9. Molecular dynamics simulation

The helicase protein is an ideal target to develop anti-viral drugs due to its sequence conservation and indispensability in all coronavirus species [30]. Hence, the helicase-ginsenoside Rg4 complex was selected for further molecular dynamics simulation to verify the stability and dynamic interaction. As shown in Fig. 9,
the root-mean-square deviation curve of the helicase backbone exhibited a smooth fluctuation after 6 ns and maintained an average value of 0.4 nm, which suggested that the combination of helicase and ginsenoside Rg4 is relatively stable. The fluctuation of the amino acid residues represented by the root-mean-square fluctuation was mostly within the range of 0.07 to 0.5 nm. The major fluctuations were observed around residue numbers 346 and 476, and in between 550–600, indicating that the protein had greater residue flexibility in these regions. From the Gibbs free energy landscape, the helicase-ginsenoside Rg4 complex was in its lowest binding free energy (0.0 kJ/mol) in the dark blue region, suggesting a good stability of the ligand–protein complex.

Fig. 5. The protein–protein interaction (PPI) network and the hub genes. A: the PPI network; B: the relationship between hub genes, chemical constituents and herbs; C: the top ten hub genes.
4. Discussion

Severe COVID-19 patients often develop acute respiratory distress syndrome and multiple organ dysfunction syndromes with a relatively high mortality rate that is related to “cytokine storm” [31]. To date, there are still no specific antiviral drugs that target SARS-COV-2. In the previous multicenter prospective clinical trial, SHG showed a significant therapeutic effect in severe COVID-19 [9]. Moreover, another retrospective study conducted by our group has shown a reduction in the level of inflammatory factors such as IL-6, IL-10 and CRP in the SHG treatment group [32]. It can be inferred that SHG reduces inflammation factors and suppress the inflammatory response in severe COVID-19 patients.

In this study, network pharmacology analysis was used to further investigate the targets and predict the mechanisms of SHG in the treatment of severe COVID-19. A total of 131 potential therapeutic target genes were obtained, including HSP90AA1, MMP9, CXCL8, PTGS2, IFNG, DNMT1, TYMS, MDM2, HDAC3 and ABCB1, which were identified as hub genes. Among them, HSP90AA1 was the most critical target in the PPI network. HSP90AA1 is a highly-conserved molecular chaperone that promotes the maturation, structural maintenance, and regulation of specific target proteins. Recent studies showed that the level of HSP90AA1 was higher in SARS-CoV-2-infected host cells and inhibition of the HSP90 activity reduced both the rate of viral replication and expression of pro-inflammatory cytokines [33]. MMP9 is a secreted protein that plays an essential role in local proteolysis of the extracellular matrix. MMP9 has been widely studied in acute lung injury and reported to have a relationship with COVID-19 [34]. As the upregulation of MMP9 can promote the neutrophils-mediated inflammatory response, MMP9 is considered to be an immune-related gene that can affect the clinical severity of COVID-19 [18]. CXCL8 commonly encodes IL-8, which is a major mediator of the inflammatory response. Cambier et al. [35] reported elevated expression of chemokines, including CXCL1, CXCL8, CXCL11 and CXCL12x, in broncho-alveolar lavage fluids of COVID-19 patients. IFNG encodes a soluble cytokine secreted by both the innate and adaptive immune systems. Elevated levels of IFNG have been found in severe COVID-19 patients and are thought to exacerbate the cytokine storm [36]. PTGS2 encodes the inducible isozyme involved in the
prostaglandin biosynthesis associated with mitogenesis and inflammation. Both IFNG and PTGS2 participate in COVID-19 and are associated with the disease severity [37]. We found that most of these hub genes involved in inflammation and immunity have played a crucial role in the development of COVID-19. Hence, these hub genes can be confirmed as therapeutic targets for SHG.

Severe cases of COVID-19 can be defined as sepsis induced by SARS-CoV-2 infection, which causes the maladjusted response of the body and deadly organ failure [38]. In addition, ACE2, a functional receptor for SARS-CoV-2, is widely distributed in multiple organs including the lungs, heart, kidneys, brain, intestine and testes [39]. Although ACE2 is rarely expressed in immune cells, some immune cells can be infected by SARS-CoV-2 because CD147 and CD26, which are strongly expressed in nearly all immune cells, may act as secondary receptors [40,41]. Therefore, we utilized BioGPS to observe the distribution of all therapeutic targets in the body and constructed the target-organ location network to explore the potential localization of SHG activity in the body. The results revealed that the therapeutic targets are highly related to immune cells, reflecting the immunomodulatory effect of SHG on severe COVID-19. Further, the therapeutic targets are also expressed specifically in the brain, lymphoid tissues, heart, gastrointestinal tract and endocrine tissues, indicating a synergistic therapeutical effect of SHG on the whole body.

GO and KEGG enrichment analyses were carried out to explore the underlying mechanism of SHG in treating severe COVID-19. The BP domain was linked to the responses to various external stimuli, such as drugs, decreased oxygen levels, and regulation of metabolic process. The GO domain suggested that SHG played an important role in the process of host response to and defense against infections. In terms of KEGG analysis, the annotation genes were mainly enriched in neuroactive ligand-receptor interactions and calcium signaling pathways. A previous study has reported that neuroactive ligand-receptor interactions may be involved in the pain response process [42]. Thus, we infer that SHG may have some palliative effect on myalgias, headache and abdominal pain caused by the virus infection. Another study proved that calcium signaling is an integral part of the integrin and chemokine signal-

Fig. 7. The GO and KEGG enrichment analysis with the 131 targets. A: GO biological process (BP) analysis; B: GO cellular composition (CC) analysis; C: GO molecular function (MF) analysis; D: KEGG pathway analysis. KEGG: Kyoto Encyclopedia of Genes and Genomes; GO: Gene Ontology.
Docking scores between the key chemical constituents of Shenhuang Granule and 2019-nCov protein targets.

| Protein target         | Affinity score (kcal/mol) |
|------------------------|---------------------------|
|                        | 2 | 11 | 14 | 29 | 34 | 37 | 38 | 39 | 40 | 42 |
| Mpro                   | -5.5 | -7.6 | -8.3 | -7.7 | -7.4 | -7.1 | -6.4 | -7.2 | -8.6 | -7.2 |
| Plpro                  | -5.9 | -9.7 | -9.3 | -9.1 | -8.4 | -9.7 | -10.1 | -8.3 | -8.3 | -7.9 |
| Nsp3 (AMP site)        | -5.4 | -7.6 | -7.7 | -7.9 | -7.6 | -7.5 | -7.7 | -7.6 | -8.9 | -7.7 |
| Nsp3 (MES site)        | -6.3 | -7.5 | -7.6 | -7.6 | -8.5 | -8.9 | -7.6 | -7.8 | -8.4 | -7.7 |
| RdRp with RNA          | -7.3 | -9.8 | -9.2 | -10.6 | -8.6 | -9.6 | -9.3 | -8.4 | -11.9 | -8.2 |
| RdRp without RNA       | -5.7 | -7.7 | -7.9 | -8.1 | -7.6 | -7.8 | -7.7 | -7.1 | -8.3 | -7.1 |
| Helicase (ADP site)    | -5.1 | -7.1 | -6.9 | -6.7 | -6.8 | -7.7 | -7.2 | -6.5 | -7.8 | -6.5 |
| Helicase (NCB site)    | -5.5 | -7.4 | -8.5 | -8.4 | -8 | -10.1 | -8.8 | -7.3 | -9.2 | -7.5 |
| Nsp14 (ExoN)           | -5.3 | -7.3 | -7.7 | -8.6 | -7.5 | -9 | -7.7 | -7 | -8.9 | -7.3 |
| Nsp14 (N7-MTase)       | -6.6 | -8.6 | -9.5 | -8.9 | -9.1 | -8.3 | -8.3 | -8.8 | -8.3 | -9.1 |
| Nsp15 (endoribonuclease)| -5.3 | -6.4 | -7 | -7.5 | -7.7 | -8.1 | -7.2 | -7.5 | -8.1 | -7.6 |
| Nsp16 (GTa site)       | -6.1 | -8.7 | -8 | -9.2 | -8 | -9.9 | -9 | -8 | -9.7 | -8.1 |
| Nsp16 (MGP site)       | -5.1 | -7 | -8 | -7.9 | -7 | -7.6 | -7.7 | -7.1 | -8.3 | -7.2 |
| Nsp16 (SAM site)       | -5.9 | -8 | -8.1 | -8.8 | -7.3 | -9.9 | -8.7 | -7.2 | -9.6 | -7.1 |
| N protein              | -5.4 | -7.5 | -8.8 | -7.7 | -8.6 | -8.7 | -8.3 | -8.8 | -8.7 | -8.6 |

The details of the constituents represented by the numbers are shown in Table 1. ADP: adenosine diphosphate; AMP: adenosine monophosphate; ExoN: N-terminal exoribonuclease; GTA: 7-methyl-GpppA; MES: 2-(N-morpholino)-ethanesulfonic acid; MGP: 7-methyl-guanosine-5’-triphosphate; Mpro: main protease; Nsp: nonstructural protein; PLpro: papain-like protease; RdRp: RNA-dependent RNA polymerase; SAM: S-Adenosylmethionine.

5. Conclusion

Our study investigated the targets and predicted the mechanisms of SHG action in the treatment of severe COVID-19 using network pharmacology, molecular docking and molecular dynamics simulation. Multiple active chemical constituents in SHG regulated multiple targets to inhibit virus invasion and cytokine storm through multiple signaling pathways, which provides a scientific basis for clinical applications and further experiments. Our research suggests that SHG may be a promising complementary drug for the treatment of severe COVID-19.

Funding

This study was supported by the National Key Research and Development Program (No. 2018YFC1705900), and the Emergency Committee of the World Federation of Chinese Medicine Societies and Shanghai Society of Traditional Chinese Medicine Novel Coronavirus Pneumonia Emergency Tackling Key Project (No. SJZLJZ-N01).
Fig. 8. Molecular models (3D and 2D) of the selected chemical constituents binding to the COVID-19 protein targets. GTA: 7-methyl-GpppA; NCB site: nucleic acid binding site; Nsp16: nonstructural protein16; PLpro: papain-like protease; RdRp with RNA: RNA-dependent RNA polymerase; SAM: S-Adenosylmethionine. Green dotted lines: hydrogen bonds; Red combs: hydrophobic contacts.
Authors’ contributions

FBJ conceived and designed the research. XXR, ZW, WXX, YHQ, SYT, PYT, WB, PW, SLH and GQ performed the acquisition and analysis of data. XXR analyzed the data. FBJ and ZS supervised the research. XXR and ZW wrote the original draft. FBJ and ZS reviewed and edited the manuscript. All authors have read and agreed to the published version of the manuscript.

Acknowledgement

We thank Shanghai Standard Technology Co., Ltd. for TCM decoction chemical analysis and identification reported in this paper.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Appendix A Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.joim.2022.07.005.

References

[1] World Health Organization. Coronavirus disease (COVID-19) pandemic. (2021-11-11). https://www.who.int/emergencies/diseases/novel-coronavirus-2019.

[2] Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020;323(12):1329–42.

[3] Tan E, Song J, Deane AM, Plummer MP. Global impact of coronavirus disease 2019 infection requiring admission to the ICU: a systematic review and screening of its bioactive compounds in inhibiting Staphylococcus aureus by UPLC-Q-TOF/MS. J Pharm Biomed Anal 2020;180:113089.

[4] Tao Q, Du J, Li X, Zeng J, Tan B, Xu J, et al. Network pharmacology and molecular docking analysis on molecular targets and mechanisms of Huashi Baidu injection in the treatment of COVID-19. Drug Dev Ind Pharm 2020;46(8):1345–53.

[5] Tianyu Z, Liying G. Identifying the molecular targets and mechanisms of Xuebijing injection for the treatment of COVID-19 via network pharmacology and molecular docking. Bioengineered 2021;12(1):2274–87.

[6] Zhao J, Tian S, Lu D, Yang J, Zeng H, Zhang F, et al. Systems pharmacological study illustrates the immune regulation, anti-infection, anti-inflammation, and multi-organ protection mechanism of Qing-Fei-Pai-Du decoction in the treatment of COVID-19. Pymedicine 2021;85:153315.

[7] Hao Y, Huo J, Wang T, Sun G, Wang W. Chemical profiling of Cortex pootplet and screening of its bioactive compounds in inhibiting Staphylococcus aureus by UPLC-Q-TOF/MS. J Pharm Biomed Anal 2020;180:113089.

[8] Ru J, Li P, Wang J, Zhou W, Li B, Huang C, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J Cheminform 2014;6:13.

[9] Zhou S, Feng J, Xie Q, Huang T, Xu Z, Zhou D, et al. Traditional Chinese medicine Shenhuang Granule in patients with severe/critical COVID-19: a randomized controlled multicenter trial. Pymedicine 2021;89:153612.

[10] Yuan H, Ma Q, Cui H, Liu G, Zhao X, Li W, et al. How can synergism of traditional medicines benefit from network pharmacology? Molecules 2017;22(7):1135.

[11] Tao Q, Du J, Li X, Zeng J, Tan B, Xu J, et al. Network pharmacology and molecular docking analysis on molecular targets and mechanisms of Huashi Baidu injection in the treatment of COVID-19. Drug Dev Ind Pharm 2020;46(8):1345–53.

[12] Tianyu Z, Liying G. Identifying the molecular targets and mechanisms of Xuebijing injection for the treatment of COVID-19 via network pharmacology and molecular docking. Bioengineered 2021;12(1):2274–87.

[13] Zhao J, Tian S, Lu D, Yang J, Zeng H, Zhang F, et al. Systems pharmacological study illustrates the immune regulation, anti-infection, anti-inflammation, and multi-organ protection mechanism of Qing-Fei-Pai-Du decoction in the treatment of COVID-19. Pymedicine 2021;85:153315.

[14] Hao Y, Huo J, Wang T, Sun G, Wang W. Chemical profiling of Cortex pootplet and screening of its bioactive compounds in inhibiting Staphylococcus aureus by UPLC-Q-TOF/MS. J Pharm Biomed Anal 2020;180:113089.

[15] Ru J, Li P, Wang J, Zhou W, Li B, Huang C, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J Cheminform 2014;6:13.

[16] Daina A, Michielin O, Zoete V. SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules. Nucelic Acids Res 2019;47(W1):W357–64.

[17] Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: archive for functional genomics data sets—update. Nucleic Acids Res 2013;41(Database issue):D991–5.

[18] Zhang Q, Meng Y, Wang K, Zhang X, Chen W, Sheng J, et al. Inflammation and antiviral immune response associated with severe progression of COVID-19. Front Immunol 2021;12:631226.

[19] Zhou C, Soufan O, Ewald J, Hancock REW, Basu N, Xia J. NetworkAnalyst 3.0: a visual analytics platform for comprehensive gene expression profiling and meta-analysis. Nucelic Acids Res 2019;47(W1):W234–41.

[20] Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003;13(11):2498–504.

[21] Szklarczyk D, Morris JR, Cook H, Kuhn M, Wyder S, Simonovic M, et al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res 2017;45(D1):D362–8.

[22] Wu C, Orozco C, Boyer J, Leglise M, Goodale S, Batavol S, et al. BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources. Genome Biol 2009;10(11):R130.

[23] Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics 2012;16(5):284–7.

[24] Xin X, Song X, Guan W, Qiu H, Du B, Li Y, et al. A multicenter prospective cohort study of Xuebijing injection in the treatment of severe coronavirus disease 2019. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2021;33(7):774–78 [Chinese with abstract in English].

[25] Wang Y, Lu C, Li H, Qi W, Ruan L, Bian Y, et al. Efficacy and safety assessment of severe COVID-19 patients with Chinese medicine: a retrospective case series study at early stage of the COVID-19 epidemic in Wuhan, China. J Ethnopharmacol 2021;277:11388.

[26] Zhi N, Liu R, Liang N, Ma Y, Ge Y, Yi H, et al. Association between early treatment with Qingfei Paidu decoction and favorable clinical outcomes in patients with COVID-19: a retrospective multicenter cohort study. Pharmacol Res 2020;161:105290.
[30] Perez-Lemus GR, Menéndez CA, Alvarado W, Byléhn F, de Pablo JJ. Toward wide-spectrum antivirals against coronaviruses: molecular characterization of SARS-CoV-2 NSP13 helicase inhibitors. Sci Adv 2022;8(1):eabj4526.

[31] Iwasaki M, Saito J, Zhao H, Sakamoto A, Hirota K, Ma D. Inflammation triggered by SARS-CoV-2 and ACE2 augment drives multiple organ failure of severe COVID-19: molecular mechanisms and implications. Inflammation 2021;44(1):13–34.

[32] Feng J, Fang B, Zhou D, Wang J, Zou D, Yu G, et al. Clinical effect of traditional Chinese medicine Shenhuang Granule in critically ill patients with COVID-19: a single-centered, retrospective, observational study. J Microbiol Biotechnol 2021;31(3):380–6.

[33] Wyler E, Mösbauer K, Franke V, Diag A, Gottula LT, Arsiè R, et al. Transcriptomic profiling of SARS-CoV-2 infected human cell lines identifies HSP90 as target for COVID-19 therapy. iScience 2021;24(3):102151.

[34] Ueland T, Holter JC, Holten AR, Muller KE, Lind A, Bekken GK, et al. Distinct and early increase in circulating MMP-9 in COVID-19 patients with respiratory failure. J Infect 2020;81(3):e41–3.

[35] Cambier S, Metzemaekers M, Carvalho AC, Nooyens A, Jacobs C, Vanderbeke L, et al. Atypical response to bacterial co-infection and persistent neutrophilic broncho-alveolar inflammation distinguish critical COVID-19 from influenza. JCI Insight 2022;7(1):e155055.

[36] Chowdhury UN, Faruque MO, Mehedy M, Ahmad S, Islam MB, Shoombuatong W, et al. Effects of Bacille Calmette Guerin (BCG) vaccination during COVID-19 infection. Comput Biol Med 2021;138:104891.

[37] Lin HY. The severe COVID-19: a sepsis induced by viral infection? And its immunomodulatory therapy. Chin J Traumatol 2020;23(4):190–5.

[38] Chung MK, Kamin S, Saef J, Bergmair C, Barnard J, Lederman MM, et al. SARS-CoV-2 and ACE2: the biology and clinical data settling the ARB and ACEI controversy. Ebiomedicine 2020;58:102907.

[39] Radzikowska U, Ding M, Tan G, Zhakparov D, Peng Y, Wawrzyniak P, et al. Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors. Allergy 2020;75(11):2829–45.

[40] Berthelot JM, Lioté F, Maujars Y, Sibilia J. Lymphocyte changes in severe COVID-19: delayed over-activation of STING? Front Immunol 2020;11:607069.

[41] Deng X, Wang D, Wang S, Wang H, Zhou H. Identification of key genes and pathways involved in response to pain in goat and sheep by transcriptome sequencing. Biol Res 2018;51(1):25.

[42] Immler R, Simon SI, Sperandio M. Calcium signalling and related ion channels in neutrophil recruitment and function. Eur J Clin Invest 2018; 48 Suppl 2 (Suppl 2): e12964.

[43] Song X, Qian Y. IL-17 family cytokines mediated signaling in the pathogenesis of inflammatory diseases. Cell Signal 2013;25(12):2335–47.

[44] Patin EC, Orr SJ, Schaible UE. Macrophage inducible C-type lectin as a multifunctional player in immunity. Front Immunol 2017;8:861.

[45] Kawasaki T, Kawai T. Toll-like receptor signaling pathways. Front Immunol 2014;5:461.

[46] Abu-Ed R, Ward FJ. Targeting the PI3K/Akt/mTOR pathway: a therapeutic strategy in COVID-19 patients. Immunol Lett 2021;240:1–8.

[47] Mei M, Tan X. Current strategies of antiviral drug discovery for COVID-19. Front Mol Biosci 2021;8:671263.